Swoop Partners with IPM.ai for Health Marketing Optimization

Real World Data can now be used for precision cross-channel pharmaceutical marketing campaigns

CAMBRIDGE, MA. – January 24, 2019 – Swoop, the company driving better patient outcomes through AI-generated digital audiences for the life sciences industry, today announced an exclusive partnership with health data provider IPM.ai to leverage their database of the medical histories of 280 million Americans in order to serve ads that are optimized towards unique diagnosed visitors (CPUDV).

This makes Swoop the only digital advertising platform that offers real-time optimization for the metric that is most closely linked to prescription lift and is a powerful indicator of audience quality. This proprietary technology will allow pharmaceutical marketers the ability to optimize against metrics traditionally used only for measurement. Increasing the amount of media spend that is going towards a diagnosed patient for your disease state will both increase ROI as well as help eliminate fraudulent traffic.

"This is a giant step forward for the entire pharmaceutical marketing industry," says Swoop CEO and co-founder Ron Elwell. "Brands have had access for some time to CPUDV and prescription lift data, but it's always been a trailing indicator, coming out months after the media has run, with no ability to actually improve performance during a campaign. This allows us to leverage what digital is good at: making optimizations against real-world health outcomes that drive sales.

"AI and big data have always held the promise of driving more informed and strategic decisions," said Elwell. "By combining years of health data on 280 million people, Swoop has brought this ability to pharmaceutical marketers. No longer is it measurement for measurement's sake, but rather a powerful strategic tool that brings real-time optimization of a real-world result."

About Swoop
Swoop empowers the world’s leading pharmaceutical brands to better-educate patients about disease states and the therapies that could remedy their conditions, as well as enable them to become active participants in their treatment journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement uncovers unique target audiences for precisely activating patient populations and their healthcare ecosystems through cross-channel marketing strategies. By utilizing artificial intelligence in conjunction with a real-world evidence and outcomes research data universe of over 300 million de-identified patient journeys over ten years and 65 billion anonymous consumer interactions, Swoop's patient segments are superior in audience quality, lead to optimal conversion, and drive increased Rx lift.

About IPM.ai
IPM.ai is an Insights as a Service (IaaS) provider that empowers the world’s leading life sciences companies to better understand and improve the lives of patients through the development and commercialization of precision medicine for specialty and rare diseases. IPM.ai’s system of insight streamlines market assessment, patient finding, treatment journey mapping, healthcare provider discovery, key opinion leader identification and brand activation by utilizing granular-level longitudinal analytics, artificial intelligence in conjunction with real-world evidence, social determinants of health, and an outcomes research data universe of over 300 million de-identified patient journeys spanning a decade.